Neuronetics (STIM) Scheduled to Post Quarterly Earnings on Tuesday

Neuronetics (NASDAQ:STIM) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, May 7th. Analysts expect Neuronetics to post earnings of ($0.33) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Neuronetics (NASDAQ:STIM) last posted its earnings results on Tuesday, March 5th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.07. Neuronetics had a negative return on equity of 72.76% and a negative net margin of 42.31%. The company had revenue of $20.31 million for the quarter, compared to analyst estimates of $19.73 million. During the same quarter last year, the company earned ($0.30) earnings per share. On average, analysts expect Neuronetics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Neuronetics Trading Up 8.9 %

NASDAQ STIM opened at $3.81 on Friday. The company has a current ratio of 4.73, a quick ratio of 4.33 and a debt-to-equity ratio of 1.73. The business has a fifty day simple moving average of $3.96 and a 200 day simple moving average of $2.91. Neuronetics has a 12 month low of $1.03 and a 12 month high of $5.07. The firm has a market capitalization of $114.20 million, a P/E ratio of -3.56 and a beta of 2.50.

Analyst Ratings Changes

A number of research firms recently weighed in on STIM. Piper Sandler reissued an “overweight” rating and set a $8.00 price target (up from $7.00) on shares of Neuronetics in a research report on Wednesday, March 6th. William Blair reaffirmed a “market perform” rating on shares of Neuronetics in a report on Tuesday, March 26th.

Insider Transactions at Neuronetics

In related news, EVP William Andrew Macan sold 22,377 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $3.16, for a total transaction of $70,711.32. Following the completion of the sale, the executive vice president now owns 395,359 shares in the company, valued at $1,249,334.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Stephen Furlong sold 21,272 shares of Neuronetics stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $3.33, for a total value of $70,835.76. Following the completion of the sale, the chief financial officer now owns 487,761 shares of the company’s stock, valued at approximately $1,624,244.13. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP William Andrew Macan sold 22,377 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $3.16, for a total transaction of $70,711.32. Following the sale, the executive vice president now directly owns 395,359 shares in the company, valued at $1,249,334.44. The disclosure for this sale can be found here. Insiders have sold 150,279 shares of company stock worth $489,167 in the last ninety days. Company insiders own 9.80% of the company’s stock.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.